# CAVALLI (NCT02055820)

> A Study Evaluating the Safety, Efficacy and Pharmacokinetics of Venetoclax Combined With Chemotherapy in Participants With B-Cell Non-Hodgkin's Lymphoma (NHL) and DLBCL

No report yet. It can be ordered.

- Drugs tested: venetoclax plus R-CHOP; venetoclax plus G-CHOP
- Indication: B-cell non-Hodgkin lymphoma

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT02055820
- Phase: PHASE1, PHASE2
- Status: COMPLETED
- Sponsor: Hoffmann-La Roche
- Conditions: Lymphoma, Non-Hodgkin
- Interventions: Venetoclax; Cyclophosphamide; Obinutuzumab; Rituximab; Doxorubicin; Vincristine; Prednisone
- Enrollment: 267
- Primary outcome: Safety: Number of Participants With Dose-Limiting Toxicities (DLTs)
- Primary outcome: Percentage of Previously Untreated DLBCL Participants With Complete Response (CR) Defined by Positron Emission Tomography-Computed Tomography (PET/CT) Scan Using the Modified Lugano Classification Assessed by Independent Review Committee (IRC)
- Primary outcome: Percentage of Participants With CR Defined by PET/CT Scan in Previously Untreated DLBCL Co-Expressing Both Bcl-2 and c-Myc Proteins (DE-DLBCL) Participants Assessed by IRC

## Indexed commentary on CAVALLI so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- X threads: 3

## Order

Focused, $750, price fixed at order: https://www.erudio.com/contact?report=cavalli-nct02055820